We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

7 hedge funds and large institutions have $4.49M invested in Galmed Pharmaceuticals in 2017 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more capital invested

Capital invested by funds: $3.14M → $4.49M (+$1.35M)

0% more ownership

Funds ownership: 0.01% → 0.01% (+0%)

30% less funds holding

Funds holding: 10 → 7 (-3)

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
7
Holders Change
-3
Holders Change %
-30%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$287K
2
VKH
Virtu KCG Holdings
New York
+$89.4K
3
Morgan Stanley
Morgan Stanley
New York
+$63.8K

Top Sellers

Rank Fund Capital Flow
1
SKK
Shepherd Kaplan Krochuk
Massachusetts
-$101K
2
MC
Menta Capital
California
-$93K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$66K
4
Creative Planning
Creative Planning
Kansas
-$4K
5
Bank of America
Bank of America
North Carolina
-$2K

GLMD Hedge Fund Activity: Q1 2017 in Review

7 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2017, worth a combined $4.49M — up 43% from $3.14M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of GLMD and 1 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was 683 Capital Management, adding an estimated $287K. The largest seller was Shepherd Kaplan Krochuk, exiting entirely with an estimated $101K sold.

  • 7 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2017, down from 10 in Q4 2016.
  • Funds reported $4.49M of Galmed Pharmaceuticals stock for Q1 2017, up 43% quarter-over-quarter.
  • 1 fund opened new Galmed Pharmaceuticals positions in Q1 2017 and 4 closed out, a net change of -3 holders.
  • The largest Galmed Pharmaceuticals buyer in Q1 2017 was 683 Capital Management, an estimated $287K added.
  • The largest Galmed Pharmaceuticals seller in Q1 2017 was Shepherd Kaplan Krochuk, an estimated $101K sold.

Based on aggregated 13F filings for Q1 2017.